A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Seven years ago, researchers caught an unexpected phenomenon on film: A pool of red dye that somehow 'knew' how to solve a maze filled with milk. Propelled forward by a couple drops of soap, it ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Maze Therapeutics (NASDAQ:MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced ...

In this week's Turtle Bay Tuesday, the Exploration Park's Mission Aerospace exhibit invites visitors to embark on an ...